Telomir Pharmaceuticals (NASDAQ:TELO) Posts Quarterly Earnings Results, Misses Expectations By $0.72 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) released its quarterly earnings data on Thursday. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.72), Zacks reports.

Telomir Pharmaceuticals Trading Up 3.8%

Shares of TELO traded up $0.04 during midday trading on Friday, reaching $1.09. 53,441 shares of the company were exchanged, compared to its average volume of 105,298. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.25. The company has a market cap of $74.96 million, a price-to-earnings ratio of -1.20 and a beta of -0.24. Telomir Pharmaceuticals has a 1-year low of $0.89 and a 1-year high of $2.09.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Institutional Investors Weigh In On Telomir Pharmaceuticals

A number of large investors have recently modified their holdings of TELO. Bank of America Corp DE raised its holdings in shares of Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company’s stock valued at $61,000 after buying an additional 10,880 shares during the period. Qube Research & Technologies Ltd purchased a new position in Telomir Pharmaceuticals in the 2nd quarter worth approximately $33,000. Geode Capital Management LLC grew its position in Telomir Pharmaceuticals by 14.0% in the fourth quarter. Geode Capital Management LLC now owns 223,549 shares of the company’s stock valued at $297,000 after acquiring an additional 27,519 shares in the last quarter. XTX Topco Ltd acquired a new stake in Telomir Pharmaceuticals in the fourth quarter valued at approximately $53,000. Finally, Jane Street Group LLC purchased a new stake in shares of Telomir Pharmaceuticals during the second quarter valued at approximately $62,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.